Selecta Biosciences, Inc.
SELBNASDAQHealthcare
$0.88
$-0.08(-8.00%)
Market Cap$135200754
P/E Ratio—
52W High$1.99
52W Low$0.785
Selecta Biosciences, Inc. (SELB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SELB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$1.46
Revenue
$0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
SELB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 30, 2026 | — | -$1.46 | — | $0.00B | — | — |
| — Q1 FY2026 | Mar 9, 2026 | — | -$3.47 | — | $0.00B | — | — |
| ◌ Q3 FY2024 | Aug 15, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 2, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Mar 7, 2024 | -$0.05 | — | — | — | — | — |
| ▲ Q4 FY2023 | Nov 2, 2023 | -$0.07 | -$0.01 | +85.7% | $0.01B | $0.01B | -40.5% |
| ▲ Q3 FY2023 | Aug 17, 2023 | -$0.09 | -$0.07 | +22.2% | $0.01B | $0.01B | -52.7% |
| ▼ Q2 FY2023 | May 4, 2023 | -$0.08 | -$0.11 | -37.5% | $0.01B | $0.01B | -49.8% |
Q2 FY2026
Apr 30, 2026
EPS Actual
-$1.46
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2026
Mar 9, 2026
EPS Actual
-$3.47
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 15, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 2, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 7, 2024
EPS Actual
—
EPS Est.
-$0.05
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 2, 2023Beat
EPS Actual
-$0.01
EPS Est.
-$0.07
EPS Surpr.
+85.7%
Revenue
$0.01B
Q3 FY2023
Aug 17, 2023Beat
EPS Actual
-$0.07
EPS Est.
-$0.09
EPS Surpr.
+22.2%
Revenue
$0.01B
Q2 FY2023
May 4, 2023Miss
EPS Actual
-$0.11
EPS Est.
-$0.08
EPS Surpr.
-37.5%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $-0.12 | $-0.07 | $-0.03 | 6 |
| Q3 FY2023 | $-0.13 | $-0.08 | $0.05 | 6 |
| Q1 FY2022 | $1.43 | $1.43 | $1.43 | 16 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 6 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2022 | $0.0B | $0.0B | $0.0B | 14 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 30, 2026 | — | $0.67 | — | — |
| — Q1 FY2026 | Mar 9, 2026 | — | $0.67 | — | — |
| ▲ Q4 FY2023 | Nov 2, 2023 | +85.7% | $1.16 | $1.18 | +1.72% |
| ▲ Q3 FY2023 | Aug 17, 2023 | +22.2% | $1.09 | $1.12 | +2.75% |
| ▼ Q2 FY2023 | May 4, 2023 | -37.5% | $1.15 | $1.07 | -6.96% |
| ▼ Q1 FY2023 | Mar 2, 2023 | -154.9% | $1.60 | $1.58 | -1.25% |
| ▼ Q4 FY2022 | Nov 3, 2022 | -777.2% | $1.63 | $1.69 | +3.68% |
| ▲ Q3 FY2022 | Aug 4, 2022 | +175.0% | $1.65 | $1.88 | +13.94% |
Q2 FY2026—
Report Date
Apr 30, 2026
EPS Beat/Miss
—
Price Before
$0.67
Price After
—
Q1 FY2026—
Report Date
Mar 9, 2026
EPS Beat/Miss
—
Price Before
$0.67
Price After
—
Q4 FY2023+1.72%
Report Date
Nov 2, 2023
EPS Beat/Miss
+85.7%
Price Before
$1.16
Price After
$1.18
Q3 FY2023+2.75%
Report Date
Aug 17, 2023
EPS Beat/Miss
+22.2%
Price Before
$1.09
Price After
$1.12
Q2 FY2023-6.96%
Report Date
May 4, 2023
EPS Beat/Miss
-37.5%
Price Before
$1.15
Price After
$1.07
Q1 FY2023-1.25%
Report Date
Mar 2, 2023
EPS Beat/Miss
-154.9%
Price Before
$1.60
Price After
$1.58
Q4 FY2022+3.68%
Report Date
Nov 3, 2022
EPS Beat/Miss
-777.2%
Price Before
$1.63
Price After
$1.69
Q3 FY2022+13.94%
Report Date
Aug 4, 2022
EPS Beat/Miss
+175.0%
Price Before
$1.65
Price After
$1.88
Avg Beat Reaction+6.14%
Avg Miss Reaction-1.51%
Beat Rate3 / 8 quarters
Largest Move+13.94% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SELB ends December
Selecta Biosciences, Inc. (SELB) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-1.46 (in line with the analyst consensus of —). SELB has beaten EPS estimates for 2 consecutive quarters. The next SELB earnings date is expected around September 1, 2026.
Each quarter, investors track SELB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SELB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SELB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SELB earnings · 4 questionsSelecta Biosciences, Inc.'s next earnings report is expected around September 1, 2026. SELB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SELB historically reports after market close (AMC).
SELB earnings datewhen is SELB earningsSELB next earnings datewhen does SELB report earningsSELB earnings calendar
▸ Source: FMP · Selecta Biosciences, Inc. SEC filings · US GAAP · Selecta Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026